Drug intelligence / Profile preview

EV104b

Development stage: Preclinical
Lead developer: Enveric Biosciences
Modality: Small Molecules

Overview

EV104b is a preclinical new chemical entity developed by Enveric Biosciences using technology licensed from Diverse Biotech. It is a covalent conjugate of cannabidiol and celecoxib intended for osteoarthritis and other pain indications. The program was designed to improve pharmacokinetics, delivery, therapeutic synergy, tolerability, and long-term efficacy relative to existing pain therapies; Enveric reported that in vitro characterization was underway and that the EV104 conjugates were covered by a provisional United States patent application for inflammatory medical conditions.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CB (Cannabinoid receptors)

Beyond the preview

Go deeper on EV104b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV104b.

Explore the full profile